@article{fdi:010094856,
  title = {{L}ong-term sequelae in {E}bola {V}irus disease survivors receiving anti-{E}bola virus therapies in the {D}emocratic {R}epublic of the {C}ongo : a prospective cohort study},
  author = {{D}ilu-{K}eti, {A}. and {T}ovar-{S}anchez, {T}. and {C}uer, {B}enjamin and {N}kuba-{N}daye, {A}. and {M}ukadi-{B}amuleka, {D}. and {P}anzi-{K}alunda, {E}. and {K}itenge-{O}masumbu, {R}. and {B}ulabula-{P}enge, {J}. and {M}ambu-{M}bika, {F}. and {M}bala-{K}ingebeni, {P}. and {A}youba, {A}hidjo and {M}uyembe-{T}amfum, {J}. {J}. and {E}tard, {J}ean-{F}ran{\c{c}}ois and {C}henge, {F}. and {D}elaporte, {E}. and {A}huka-{M}undeke, {S}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground {T}he 2018-2020 {E}bola outbreak in the {D}emocratic {R}epublic of the {C}ongo marked the first major cohort of {E}bola survivors treated with advanced therapeutics, including monoclonal antibodies ({REGN}-{EB}3, ansuvimab, {ZM}app) and remdesivir. {T}his study explored factors influencing long-term sequelae in survivors who received these specific therapies.{M}ethods {A} prospective multicenter study enrolled 750 {E}bola survivors from the 10th outbreak in the {D}emocratic {R}epublic of the {C}ongo between {A}pril and {O}ctober 2020. {P}articipants were followed for 12 months to assess the recurrence of clinical sequelae according to {W}eibull and shared frailty models.{R}esults {O}f 750 of {E}bola survivors, 650 (86.7%) experienced post-{E}bola sequalae. {T}he median age of survivors was 32 years and 56.7% were female. {A}mong them, 463 (61.7%) experienced neurologic sequelae, 373 (49.7%) musculoskeletal sequelae, and 288 (38.4%) general sequelae. {G}lobally, these persisted for at least 38 months postdischarge, with slight decreases over time. {A}t enrollment (median time to baseline visit, 330 days after discharge), neurologic sequelae were more frequent in the {REGN}-{EB}3 group (hazard ratio, 2.14; 95% {CI}, 1.28-3.57) as compared with the remdesivir group. {M}usculoskeletal sequelae were associated with age (1.02; 1.00-1.03), {ZM}app treatment (3.17; 1.81-5.56), and acute-phase hemorrhagic symptoms (1.64; 1.14-2.36). {O}cular sequelae were associated with age (1.04; 1.02-1.06). {F}emale sex, older age, metabolic comorbidities, and {REGN}-{EB}3 therapy were associated with recurrent neurologic and musculoskeletal sequelae. {R}ecurrent ocular sequelae were more frequent in adults (1.02; 1.01-1.03).{C}onclusions {D}espite improved survival with monoclonal antibody therapy, our findings highlight a high incidence of neurologic sequelae in the {REGN}-{EB}3 group and musculoskeletal sequelae in the {ZM}app group as compared with the remdesivir group, as well as among older survivors, women, and those with comorbidities. {T}hese results underscore the need for targeting long-term care to effectively manage post-{E}bola sequelae.},
  keywords = {{E}bola virus disease ; {EVD} sequelae ; frailty model ; monoclonal antibody ; treatment ; {W}eibull model ; {REPUBLIQUE} {DEMOCRATIQUE} {DU} {CONGO}},
  booktitle = {},
  journal = {{O}pen {F}orum {I}nfectious {D}iseases},
  volume = {12},
  numero = {8},
  pages = {ofaf436 [13 p.]},
  ISSN = {2328-8957},
  year = {2025},
  DOI = {10.1093/ofid/ofaf436},
  URL = {https://www.documentation.ird.fr/hor/fdi:010094856},
}